Trial Profile
SGLT2 Inhibitor, Ipragliflozin, Suglat, Effect on Lipid and Glucose Metabolism Study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Dec 2020
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms SUCRE
- 26 Jun 2017 Planned End Date changed from 30 Sep 2017 to 30 Sep 2018.
- 02 Jul 2015 New trial record